Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS), including Alzheimer's.
Grifols will make a $37.5 million equity investment in the form of a cash payment in exchange for 45% of Alkahest's shares following the closing of the transaction.
In addition Grifols will provide a further payment of $12.5 million and fund the development of plasma-based products, which may be commercialized by Grifols throughout the world.
|Searching for more deal information? Current Partnering offers the following options:
Alkahest will receive milestone payments and royalties on sales of such products by Grifols.
Grifols will have two seats on Alkahest's Board of Directors and will collaborate with Alkahest researchers through the creation of a Scientific Joint Steering Committee.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies